gbola amusa md cfa head hc research
sale trade et
viral news genet medicin data disappoint high chardan pick
highlight week decemb januari unrat announc top-line data
phase ib/iia trial antisens oligonucleotid aso huntington diseas hd
placebo-control studi report reduct cerebrospin fluid csf level mutant huntingtin
mhtt protein develop select lower mhtt target singl nucleotid polymorph
ration design stereopur safe well toler compani plan
initi test higher dose trial expect read
despit statistically-signific data share finish week recal march ioni
unrat report mean reduct mhtt csf level follow administr aso
ionis-httrx unrat announc dose patient phase i/ii trial
arenavirus-bas immunotherapi treatment human papillomaviru
cancer base compani replication-attenu arenaviru therat vector platform
express highli antigen fusion protein open-label dose-escal trial design test safeti
toler preliminari efficaci hookipa expect provid preliminari data late earli
unrat publish scienc car-t cell solid tumor compani present protein claudin
possibl target solid tumor strategi base nanoparticl rna vaccin stimul
adopt transfer car-t cell nanoparticl vaccin refer car-t cell amplifi rna vaccin
carvac current test on-going clinic trial chardan top pick
portfolio close averag alpha gener across names/posit success rate see
research name buy-rat qure includ chardan
genet medicin top pick portfolio close averag alpha gener
across names/posit success rate
look forward januari januari januari neutral attend
present atlant coast retina club macula confer new york citi
weekli price move vivo genet medicin aav srna mrna vivo gene edit
srna mrna mm vivo gene edit mm contributor buy mm
upcom chardan genet medicin event contact chardan rsvp
gene express kidney emerg site gt
although gene link renal disord rel littl progress made advanc
gene therapi diseas kidney due part filter function kidney exclud protein
kda understand potenti rout vector administr professor michael barri colleagu
mayo clinic decemb publish gene therapi vector aav adv lentiviru deliv murin
kidney intraven administr via retrograd ureter ru subcapsular sc inject system deliveri
gene deliveri vector kidney gener ineffici select aav vector name
abl transduc kidney cell follow intraven deliveri transduct restrict cell
pleas refer import disclosur inform regul analyst certif found page report
glomeruli thu limit abil treat rang inherit kidney disord direct inject retrograd ureter
ru subcapsular sc rout possibl altern system deliveri find present paper
gener support altern approach howev viral vector shown leak kidney follow inject
transduc non-target tissu liver non-target organ transduct highest follow inject aav
observ author attribut smaller size aav virion aav serotyp also differ respect kidney
cell transduct follow inject among vector test led effici gene express
key take-away us advanc need method deliveri vector tropism achiev effici
gene transfer kidney activ area research among academ group exampl recal
preclin studi aav vector identifi synthet aav potenti vector therapeut transduct
human kidney cell treat fibrosi associ chronic kidney diseas also note rna-bas approach
treatment kidney diseas exampl alport syndrom genet diseas caus mutat type iv collagen
character kidney failur phase ii trial on-going sanofi unrat mirna-bas
chardan top pick gener average alpha roll januari amusa
end chardan top pick portfolio close averag alpha gener
across names/posit success rate
ad name new chardan top pick portfolio
buy meiragtx buy buy uniqur buy
sinc qure genet medicin name includ well posit
chardan genet medicin top pick portfolio
chardan drop coverag iver bio ise focu coverag area cover name
genet medicin news decemb januari
unrat announc data pib/iia trial aso huntington diseas decemb
wave life scienc unrat announc top-line data phase ib/iia trial antisens
oligonucleotid aso huntington diseas base analysi patient treat multipl
intrathec dose reduct csf level mhtt protein report
safe well toler compani plan initi test higher dose
unrat report march top-line data phase i/ii studi
aso therapeut ionis-httrx show mean reduct csf level mhtt current
phase trial huntington diseas sponsor roch unrat
unrat announc pt dose arenavirus-bas cancer decemb
unrat announc patient dose phase i/ii trial arenavirus-
base immunotherapi treatment human papillomaviru cancer
open-label dose escal expans trial conduct patient phase portion patient
divid group patient group receiv monthli inject iv administr group
includ patient access tumor receiv initi dose intratumor administr monthli
iv inject phase ii portion studi evalu alon combin inhibitor
buy close agreement nvo unrat rnai tx cardio-metabol diseas januari
unrat publish nejm data rnai therapeut akcea-apo -lrx cvd januari
xon unrat announc chang corpor focu leadership januari
intrexon corpor announc focu healthcar compani name chang
new includ wholly-own subsidiari actobio privat exemplar
genet privat major ownership triple-gen privat compani focu infecti diseas
immuno-oncolog autoimmun disord
helen sabzevari phd appoint presid ceo previous serv presid
unrat publish nejm pi/ii data gt hemophilia januari
bntx unrat publish scienc stimul car-t cell rna vaccin januari
page
publish scienc car-t cell solid tumor compani present protein claudin
possibl target solid tumor strategi base nanoparticl rna vaccin stimul adopt
mous model iv inject carvac encod led antigen express antigen present cell
apc activ nk cell singl iv dose also suffici induc profound expans
compani note advantag use carvac approach expand car-t cell includ combin
antigen-deliveri adjuvant one molecul product cost produc nanoparticl form also
reportedli low protein-bas antigen
compani mention report
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma buy lysogen oncosec medic oxford biomedica neutral vbl buy
figur select price movement week end jan vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm gensight genet therapytickerratingccm ptupsideclosechang changemc mm arbutu gene editingtickerratingccm ptupsideclosechang changemc mm logicbio pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note though avx nite acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap pharmaceut
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid technolog pharmaceut
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name bntx model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani pharmaceut
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis feldan recombinet trucod gene repair verv technolog pharmaceut
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
swedish orphan biovitrum astrazeneca
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
price prv
page
date fda rpdd
ultragenyx genetx
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genetx ultragenyx
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
